Dr. Mauro Discusses Updates in CML

Video

In Partnership With:

Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses updates in chronic myeloid leukemia.

Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses updates in chronic myeloid leukemia (CML).

There are now 4 agents approved in the frontline setting for chronic phase CML. Mauro says that novel treatments in the frontline setting for CML were a big topic during the 2017 ASH Annual Meeting, and the FDA approval of bosutinib (Bosulif) as a first-line treatment for patients with Philadelphia chromosome-positive (Ph+) solidified that.

Mauro says that another important topic in CML is how to conceptualize treatment-free remission. This is exciting, Mauro adds, because tyrosine kinase inhibitors (TKIs) have allowed patients to experience substantial remissions.

Additionally, cardio-oncology is an important consideration for physicians treating patients with CML, Mauro says, as well as investigating fourth-generation drugs.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD